PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported third-quarter results and outlined major clinical and regulatory milestones that position its lead therapy, rese-cel, as a potential first-in-class CAR T ... Read more
Mychesco - Nov 18
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) unveiled promising clinical data from its RESET-MyositisTM, RESET-SScTM, and RESET-SLETM trials evaluating rese-cel (resecabtagene autoleucel), reinforcing its potential to deliver long-lasting, drug-free ... Read more
Mychesco - Nov 06
